Biogen Idec Increases Revenue 6 percent to $1.4 Billion in the Third Quarter The Herald | HeraldOnline.com RITUXAN® (rituximab) revenues from our unconsolidated joint business arrangement were $288 million for the quarter, an increase of 8 percent year-over-year. Global in-market sales of TYSABRI in the third quarter of 2012 were $404 million, an increase ... Biogen Idec Management Discusses Q3 2012 Results - Earnings Call Transcript |
